All In Biotech

Drug Trial Radar · NCT06209580

AMT-253 in Patients With Advanced Solid Tumours

Phase I/II Study of AMT-253 in Patients With Unresectable or Metastatic Malignant Melanoma and Other Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Sep 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

96

Planned (sponsor's estimate)

Start

Jan 31, 2024

Primary completion

Apr 30, 2026

Study completion Dec 31, 2026

Sponsor

Lead sponsor
Multitude Therapeutics Inc.Industry
Sponsor type
Industry
First posted
Jan 17, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a non-randomized, open-label, multicenter Phase I/II study of AMT-253 in patients with Unresectable or Metastatic Malignant Melanoma and other Advanced Solid Tumors. This study include phase I dose escalation and phase II dose expansion.

Conditions

  • Malignant Melanoma
  • Advanced Solid Tumors

Interventions

  • AMT-253 for injectionDrug

    Administered intravenously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. DLTsTime frame: 21 days after first dose
  2. AEsTime frame: Up to 24 months
  3. SAEsTime frame: Up to 24 months
  4. ORRTime frame: Up to 24 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.